Cancer occurrence in trials using vitamin D₃ (cholecalciferol) · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D showed no clear difference in cancer occurrence in trials using vitamin D₃ (cholecalciferol) compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Cancer mortality in trials using vitamin D3 (cholecalciferol) ( · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to lower cancer mortality in trials using vitamin D₃(cholecalciferol) compared with placebo or no intervention (low certainty).
1 finding from 1 review
Adverse events ‐ Nephrolithiasis in trials using vitamin D3 combined with calcium · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…
Vitamin D may leads to higher adverse events: nephrolithiasis in trials using vitamin… compared with placebo or no intervention (low certainty).
1 finding from 1 review
Time to cessation of bleeding · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BMD Z score (lumbar spine) · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PIVKA II levels: change in PIVKA II (ng/mL) · adults and children with cystic fibrosis
1 finding from 1 review
Uncarboxylated osteocalcin: change in carboxylation of osteocalcin (% Glu‐OC) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean serum vitamin D concentrations · children under 5 years of age
1 finding from 1 review
Vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
It is very uncertain whether vitamin D given to infants changes vitamin D insufficiency: 25‐OH vitamin D < 50 nmol/L compared with vitamin D given to lactating mothers (very low certainty).
1 finding from 1 review
Vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
It is very uncertain whether vitamin D given to infants changes vitamin D deficiency: 25‐OH vitamin D < 30 nmol/L compared with vitamin D given to lactating mothers (very low certainty).
1 finding from 1 review
Serum 25‐OH vitamin D level at latest time reported nmol/L · term breastfed infants to prevent vitamin D deficiency and improve bone health
1 finding from 1 review
Bleeding complications: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in bleeding complications: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Sepsis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in sepsis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review